Whitebox Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Whitebox Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,500	Closed	-$510K	–	734
2022 Q4	$510K	Hold	50,500	–	–	0.01%	380
2022 Q3	$500K	Hold	50,500	–	–	0.01%	490
2022 Q2	$494K	Hold	50,500	–	–	0.02%	480
2022 Q1	$492K	Sell	50,500 -4,000	-7%	-$38.9K	0.01%	520
2021 Q4	$528K	Hold	54,500	–	–	0.01%	466
2021 Q3	$527K	Hold	54,500	–	–	0.01%	377
2021 Q2	$531K	Buy	+54,500	New	+$535K	0.01%	326

Whitebox Advisors's EBAC Position: Q1 2023 in Review

Whitebox Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 50,500 shares — an estimated $510K sold.

Whitebox Advisors first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $531K in Q2 2021. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Whitebox Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Whitebox Advisors sold 50,500 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $510K.
Whitebox Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Whitebox Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $531K in Q2 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Whitebox Advisors's 13F filing for Q1 2023, filed 15 May 2023.